온열 복강내 화학요법을 통한 세포감소 수술 중 링거 젖산염과 링거 젖산염과 결합된 20% 알부민의 수술 중 사용 효율성: 무작위 공개 임상 시험을 위한 프로토콜 (ALBUCHIP)
Remplissage Vasculaire Par de l'ALBUmine 휴메인 20% + 링거 젖산 비교 평가
Introduction Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is considered as the standard of care for the treatment of peritoneal metastases. Cytoreductive surgery with HIPEC is characterized by large intra operative fluid shift secondary to surgical resection, peritoneal inflammation and capillary shifts, requesting high volume of intra operative fluid therapy. Previous studies found a strong association between intra operative hypovolemia or volume overload with post operative outcomes. Albumin as an intravenous fluid has been widely studied in critical ill patients, but evaluation of its efficacy during major surgery on post operative clinical outcomes are lacking. We hypothesize that a reduction of intra operative crystalloid volume infusion by using 20% albumin during CRS with HIPEC could improve patients' prognosis. The aim of this study will be to assess the efficacy of 20% albumin combined with Ringer Lactate versus Ringer Lactate for fluid therapy during CRS with HIPEC on post operative outcome at 28 day.
Methods and analysis The study protocol has been designed and written in accordance with the Prospective randomised, comparative, controlled, prospective, open-label, with parallel group and multicentre clinical trial.
Recruitment, randomisation and allocation Information on the study and screening of patients will be conducted during the consultation of anaesthesia (= selection visit), 2 months at 3 days before the surgery. Information notice and consent form will be delivered. The day before the surgery, anaesthesiologist who will conduct the pre anaesthetic visit will be able to include patients in the study (=inclusion visit). Randomisation will be done at the inclusion visit after information and signature of consent form of voluntary patients. A randomization number will be assigned. The 1:1 randomisation will be centralized via an online interface ensuring secret group assignment, and based on predefined randomisation lists with variable-size permutation blocks, stratified by center. Randomisation will be accomplished using a computer-generated random sequence.
Randomized Open, Blinded endpoint (PROBE) design. This study is a randomised, comparative, controlled, prospective, open-label, with parallel group and multicentre clinical trial.
Intervention
- 20% Albumin + Ringer Lactate group (intervention group) Per-operative fluid therapy consisting in Ringer Lactate combined with 20% albumin. Patients will receive a bolus of 3 mL/kg on one hour of 20% albumin from anaesthetic induction. Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery.
- Control group Ringer Lactate for intra operative fluid management based on the latest scientific recommendations. As the the study is an open labelled randomized clinical trial, placebo use is not planned.
Outcome measures The primary outcome will be the Comprehensive Complication Index (CCI score) at day 28 after CRS with HIPEC. Secondary outcomes are mortality at day 28, CCI score at day 7, volume of intra operative and post operative (48h) post operative fluid therapy, cumulated incidence of surgical post operative complications, cumulated incidence of medical post operative complications, need for mechanical ventilation, renal replacement therapy between surgery and day 28, SOFA score variation between pre operative period and 48h after surgery, number of days alive out of intensive care unit and out of hospital until day 28
Sample size calculation To ensure a power of 80%, a number of patients 130 (65 patients by group) will be necessary with a reduction of 13.6 (SD 24) points of the CCI score at day 28 in the intervention group. Because of a risk of neoplastic evolution between anaesthetic consultation and randomisation (10% of early cancellation), a total of 146 patients (73 by group) will be included in the study.
Discussion In summary, ALBUCHIP study will be the first randomized clinical trial assessing efficacy of intraoperative use of 20% albumin combined with Ringer Lactate versus Ringer Lactate during CRS with HIPEC. Results yielded from this study will be helpful for vascular filling during CRS with HIPEC but, thanks to ancillary studies, to improve pathophysiological understanding of this surgery.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Jérôme Lambert, Pr
- 전화번호: +33 142499742
- 이메일: jerome.lambert@u-paris.fr
연구 연락처 백업
- 이름: Arthur Moreau, Dr
- 전화번호: +33 142499394
- 이메일: arthur.moreau@aphp.fr
연구 장소
-
-
-
Lyon, 프랑스
- 모병
- Hôpital Lyon Sud Pierre Bénite
-
연락하다:
- Anne Li
- 전화번호: +33 04 78 86 14 76
- 이메일: anne.li@chu-lyon.fr
-
Montpellier, 프랑스
- 모병
- Institut régional du Cancer de Montpellier
-
연락하다:
- Lana Zoric
- 전화번호: +33 467618538
- 이메일: Lana.Zoric@icm.unicancer.fr
-
Paris, 프랑스, 75013
- 모병
- La Pitié Salpetriere hospital
-
연락하다:
- Alexandre Sitbon
- 전화번호: +33 184827399
- 이메일: alexandre.sitbon@aphp.fr
-
Paris, 프랑스
- 모병
- Lariboisière hospital
-
연락하다:
- Nathalie Poirier
- 전화번호: +33 1 49 95 68 43
- 이메일: nathalie.poirier@aphp.fr
-
Paris, 프랑스
- 모병
- Saint Louis hospital
-
연락하다:
- Arthur Moreau
- 전화번호: +33 142499394
- 이메일: arthur.moreau@aphp.fr
-
Reims, 프랑스
- 모병
- Robert Debré hospital
-
연락하다:
- Ezechiel Bankole
- 전화번호: +33 326788801
- 이메일: ebankole@chu-reims.fr
-
Strasbourg, 프랑스
- 모병
- Hôpital Hautepierre / UIC ARMO
-
연락하다:
- Valentina FAITOT
- 전화번호: +33 388116768
- 이메일: valentina.faitot@chru-strasbourg.fr
-
Villejuif, 프랑스
- 모병
- Gustave Roussy Institute
-
연락하다:
- Stéphanie Suria
- 전화번호: +33 142114437
- 이메일: Stephanie.SURIA@gustaveroussy.fr
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male and female patients aged 18 years old and older
- Planned cytoreductive surgery with HIPEC for peritoneal carcinomatosis (from gynaecological or digestive origin)
- Patient volunteer for the study and provided written informed consent
- Patient affiliated to the French Health Insurance
Exclusion Criteria:
- Adults >75 years old
- Functional status rendering the patient ineligible for cytoreduction with CHIP (ECOG > 2 or Karnofsky index < 75)
- Pre-existing preoperative conditions affecting albuminemia (hepatic cirrhosis, nephrotic syndrome, exudative enteropathy, malnutrition)
- Severe preoperative hypoalbuminemia (albuminemia < 20 g/L)
- History of chronic left heart failure with reduced left ventricular ejection fraction (left ventricular ejection fraction < 40%)
- Patients at high risk of perioperative and postoperative pulmonary complications (atelectasis, significant pleural effusions)
- Significant ascites with preoperative respiratory repercussions
- Uncontrolled diabetes (HbA1c > 8.5%)
- Allergy to exogenous human albumin and its excipients.
- Contraindication to the administration of Ringer's lactate (history of allergy)
- Hyperkalemia > 6.0 mmol/L
- Hypercalcemia (total calcium > 2.60 mmol/L)
- Chronic use of digitalis and hyperkalemic diuretics
- Pregnancy, breastfeeding
- Known preoperative renal failure (GFR < 30 mL/min/1.73m2 or extrarenal purification)
- Recent brain trauma < 6 months (traumatic, ischemic, or hemorrhagic)
- Participation in another interventional study involving human subjects or being in the exclusion period following a previous study involving human subjects, if applicable
- Patient deprived of liberty
- Patient under guardianship or curatorship
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: 20% Albumin + Ringer Lactate group
Per-operative fluid therapy consisting in Ringer Lactate combined with 20% albumin. Patients will receive a bolus of 3 mL/kg on one hour of 20% albumin from anaesthetic induction. Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery. |
Patients randomized in the intervention group (20% albumin + Ringer Lactate) will receive, during cytoreductive surgery with HIPEC, fluid therapy consisting in Ringer Lactate (based on a fluid management protocol specifically set up for the study, and based on latest recommendations) combined with 20% albumin. Patients randomized in the intervention group will receive a bolus of 3 mL/kg on one hour of 20% albumin from anesthetic induction . Dosage of albuminemia will be done 2 hours after the end of the bolus (target of 35-45 g/L of intra operative albuminemia). Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery. |
|
활성 비교기: Control group
Ringer Lactate for intra operative fluid management based on the latest scientific recommendations. As the the study is an open labelled randomized clinical trial, placebo use is not planned. |
Ringer lactate |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Comprehensive Complication Index score
기간: At day 28
|
The Comprehensive Complication Index (CCI) is a score ranging from 0 to 100, calculated using all complications and their treatment after abdominal surgery. The CCI is that it is a linear scale ranging from 0 to 100, where 100 represents death |
At day 28
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
수술 중 및 수술 후 수액 요법의 양
기간: 수술 후 48시간
|
수술 후 48시간
|
|
|
수술 후 합병증의 누적 발생률
기간: 28일까지
|
28일까지
|
|
|
중환자실에서 생존한 일수
기간: 28일까지
|
28일까지
|
|
|
병원 밖에서 생존한 일수
기간: 28일까지
|
28일까지
|
|
|
감염성 합병증 발생률
기간: 최대 28일
|
최대 28일
|
|
|
의학적 합병증 발생률
기간: 28일까지
|
28일까지
|
|
|
중환자실 내 사망의 누적 발생률
기간: 최대 28일까지
|
최대 28일까지
|
|
|
병원 내 사망 누적 발생률
기간: 28일까지
|
28일까지
|
|
|
혈관 수축제 투여 기간(일)
기간: 최대 28일까지
|
최대 28일까지
|
|
|
알부민에 대한 알레르기 합병증을 가진 환자의 비율
기간: 133일째에
|
133일째에
|
|
|
Comprehensive Complication Index score
기간: At day 7
|
The Comprehensive Complication Index (CCI) is a score ranging from 0 to 100, calculated using all complications and their treatment after abdominal surgery. The CCI is that it is a linear scale ranging from 0 to 100, where 100 represents death |
At day 7
|
|
Number of days under mechanical ventilation outside the operating room
기간: Up to day 28
|
Between surgery and day 28 |
Up to day 28
|
|
Number of days under renal replacement therapy
기간: Up to day 28
|
Between surgery and day 28 |
Up to day 28
|
|
Sequential organ failure assessment (SOFA) score variation
기간: 48 hours after surgery
|
Between pre operative period and 48h after surgery |
48 hours after surgery
|
|
SOFA score
기간: At day 28
|
Sequential Organ Failure Assessment Score varies from 0 to 4 and permit to assess organ failure. A higher score indicates better neurological function |
At day 28
|
공동 작업자 및 조사자
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- APHP230864
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .